Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

th other medicinal products for pain, was made in reliance on NeurogesX' commitment to conduct certain post marketing studies of Qutenza following approval. Post-marketing commitments are often required by the CHMP as a condition for recommending approval. An open-label safety study of Qutenza in on-label indications is planned to be conducted following launch of Qutenza in the E.U. In addition, a protocol evaluating the clinical safety and efficacy of Qutenza in painful diabetic neuropathy will be discussed with the CHMP following approval of the MAA. It is anticipated that these studies could potentially be conducted and/or funded by a European commercial partner.

NGX-1998 is the Company's second-generation, liquid formulation of the same active ingredient found in Qutenza. The liquid formulation is being developed to address neuropathic pain conditions, providing similar efficacy in a shorter treatment time versus Qutenza. NGX-1998 has been evaluated in three Phase 1 studies and is currently being considered for entry into Phase 2 evaluation, subject to receipt of additional funding.

NeurogesX is also seeking business development partners to advance its acetaminophen and opioid prodrug product candidates.

  • NGX-9674 and NGX-5752, novel prodrugs of acetaminophen, have been evaluated in in vivo and in vitro preclinical studies and demonstrate approximately 10 times greater solubility in water versus acetaminophen.
  • NGX-1576, a novel prodrug coupling acetaminophen to a liver protectant, has been evaluated in vitro and in vivo. Equivalent dose levels of NGX-1576 in mice produced significantly less liver toxicity than acetaminophen, while additional data demonstrated the production of equivalent plasma levels of acetaminophen.
  • NGX-6052, the most advanced molecule synthesized in NeurogesX' opioid prodrug platform, has been evaluated
    '/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... note: Last month, the information security firm ... Security Threat Report . This is Symantec's attempt to get ... trees, and these woods look pretty ominous, according to Dave ... , , The name of the game today is data ...
... Brookfield, Wis. - Fiserv reported net income ... gain of $0.66 per share, with revenues rising 11 percent ... develops electronic products for the financial services industry, said net ... same quarter of 2006, but earnings per share were slightly ...
... of Wisconsin-Madison professor who has been called the father ... research lab as an adjunct professor at the University ... Independent is reporting that Thomson, who remains a ... about one month out of the year and lead an ...
Cached Biology Technology:Symantec: Cyber fraudsters look for low-hanging fruit 2Symantec: Cyber fraudsters look for low-hanging fruit 3Symantec: Cyber fraudsters look for low-hanging fruit 4Symantec: Cyber fraudsters look for low-hanging fruit 5Symantec: Cyber fraudsters look for low-hanging fruit 6Symantec: Cyber fraudsters look for low-hanging fruit 7Jamie Thomson to run California research lab 2
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with the 2015 ... of the Year Award. Credence ID has developed ... its mission of offering enrollment and identification solutions ... Credence ID was formed by experts from the ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... of researchers is releasing data today that it hopes will ... of parasites that causes a deadly trio of insect-borne diseases ... centuries. In an article to be published in today,s ... University scientist Galina Lepesheva and her team are reporting their ...
... discovery by scientists at the University of Kentucky could someday ... the brain, spinal cord and the eye. Researchers led ... in the UK College of Medicine, found that the small ... vimentin and glial fibrillary acidic protein (GFAP) implicated in ...
... DNA damage have for the first time been found in ... progressive nervous system disease called Friedreich,s ataxia (FRDA), says a ... of Pittsburgh Cancer Institute (UPCI). The findings, described today ... abnormalities that lead to the disease, as well as point ...
Cached Biology News:Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 2Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 3Kentucky study advances new target for CNS drug development 2Excess DNA damage found in cells of patients with Friedreich's ataxia 2
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (E6152) or contact ... Dim: H diam. 11.25 ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
Biology Products: